Stock Analysis: OPRX (OptimizeRx Corporation)

23
๐Ÿ“Šโ€“ 30-Min Chart
๐Ÿ“‰ Setup Type: Rising Wedge Breakdown (Bearish Reversal)

๐Ÿ”ป Trade Plan (Short Position)
โœ… Entry Zone: Below $8.78 (Breakdown Confirmation)
โœ… Stop-Loss (SL): Above $9.52 (Key Resistance Level)

๐ŸŽฏ Take Profit Targets (TPs)
๐Ÿ“Œ TP1: $7.81 (Support Level)
๐Ÿ“Œ TP2: $6.60 (Key Demand Zone)
๐Ÿ“Œ TP3: $6.00 (Major Support & Psychological Level)

๐Ÿ“Š Risk-Reward Ratio Calculation
๐Ÿ“‰ Risk (SL Distance):
$9.52 - $8.78 = $0.74 risk per trade

๐Ÿ“ˆ Reward to TP1:
$8.78 - $7.81 = $0.97 (1:1.3 R/R)

๐Ÿ“ˆ Reward to TP2:
$8.78 - $6.60 = $2.18 (1:2.95 R/R)

๐Ÿ“ˆ Reward to TP3:
$8.78 - $6.00 = $2.78 (1:3.76 R/R)

โœ… Favorable Risk-Reward Ratio with strong downside potential!

๐Ÿ” Technical Analysis & Strategy
๐Ÿ“Œ Rising Wedge Breakdown: Price is breaking below a bearish wedge pattern, signaling weakness.
๐Ÿ“Œ Key Resistance Holding: $9.52 acts as a strong rejection zone, reinforcing downside potential.
๐Ÿ“Œ Volume Confirmation: Increasing sell volume confirms bearish sentiment.
๐Ÿ“Œ Momentum Shift: Loss of upward trend momentum suggests possible trend reversal.

๐Ÿ“‰ Trade Execution & Risk Management
โœ” Wait for Confirmation: A 30-min candle close below $8.78 strengthens the breakdown.
โœ” Adjust Stop-Loss: Move SL to break-even ($8.78) after hitting TP1 ($7.81).
โœ” Partial Profit Booking Strategy:
โœ” Take 50% profits at TP1 ($7.81) and let the rest run toward TP2 & TP3.
โœ” Adjust Stop-Loss to Break-even ($8.78) after TP1 is reached.

โš ๏ธ Risks & Considerations โŒ Fake Breakdown Risk: If price reclaims $8.78, the short setup could be invalidated.
โŒ Market Conditions: Low-volume breakdowns may lead to a bounce.

๐Ÿš€ Final Thoughts โœ” Bearish Setup โ€“ Strong downside potential.
โœ” Rising Wedge Breakdown โ€“ High confluence setup.
โœ” Favorable Risk-Reward Ratio โ€“ 1:3.76 toward TP3.
๐Ÿ’ก Stick to the plan, manage risk, and trade smart! ๐Ÿš€๐Ÿ“‰

๐Ÿ”— #OPRX #ShortTrade #BearishBreakdown #TradingView #ProfittoPath ๐Ÿ’ฐ๐Ÿ“Š

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.